Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

MeiraGTx Holdings plc - Ordinary Shares (NQ:MGTX)

7.680 +0.100 (+1.32%)
Streaming Delayed Price Updated: 9:49 AM EST, Feb 18, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about MeiraGTx Holdings plc - Ordinary Shares

< Previous 1 2 3 4 Next >
News headline image
MeiraGTx Announces $30 Million Strategic Investment from Sanofi; Company Pursuing Multiple Additional Strategic Opportunities
From MeiraGTx
Via GlobeNewswire
News headline image
MeiraGTx Announces an Oral Presentation and Eight Posters at the European Society of Gene and Cell Therapy (ESGCT) 2023 Annual Congress
Multiple Posters and Oral Presentations Highlight the Depth of Innovation from MeiraGTx’s Technology Platforms for Gene and Cell Therapy 
From MeiraGTx
Via GlobeNewswire
News headline image
MeiraGTx Reports Second Quarter 2023 Financial and Operational Results
From MeiraGTx
Via GlobeNewswire
News headline image
MeiraGTx Hldgs: Q1 Earnings Insights ↗
 
Via Benzinga
News headline image
MeiraGTx Holdings's Return On Capital Employed Overview ↗
 
Via Benzinga
News headline image
MeiraGTx's Investigational Candidate Shows Improvement In Radiation Induced Dry Mouth Symptoms ↗
 
Via Benzinga
News headline image
MeiraGTx Posts Encouraging Gene Therapy Data From Eye Disorder Trial ↗
 
Via Benzinga
News headline image
MeiraGTx Announces Poster Presentation at the 2023 American Society of Gene and Cell Therapy (ASGCT) Spotlight on Immuno-Oncology
RiboCAR-T cell activity can be precisely tuned and “remotely” controlled to improve the efficacy, durability and safety of CAR-T cell therapy 
From MeiraGTx
Via GlobeNewswire
News headline image
MeiraGTx Announces its Wholly-Owned Gene Therapy Manufacturing Facility in Shannon, Ireland has Received Commercial MIA Authorization for QC Testing
From MeiraGTx
Via GlobeNewswire
News headline image
MeiraGTx's Investigational Drug Shows Improved Symptoms In Radiation-Induced Oral Dryness ↗
MeiraGTx Holdings plc (NASDAQ: MGTX) released data from the completed Phase 1 AQUAx study of AAV2-hAQP1  for grade 2/3 radiation-induced xerostomia (RIX), which includes the final 12-month data from... 
Via Benzinga
News headline image
MeiraGTx Announces Positive Clinical Data from the AQUAx Phase 1 Clinical Study of AAV2-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia
From MeiraGTx
Via GlobeNewswire
News headline image
MeiraGTx Hldgs: Q1 Earnings Insights ↗
MeiraGTx Hldgs (NASDAQ:MGTX) reported its Q1 earnings results on Thursday, May 12, 2022 at 08:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
News headline image
MeiraGTx to Present 12-month Data from All Cohorts of the Completed Phase 1 AQUAx Clinical Study and an Update on the Company’s Recently Initiated Phase 2 Study of AAV-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia on Tuesday, June 27,
From MeiraGTx
Via GlobeNewswire
News headline image
Over $125M Bet On Occidental Petroleum? Check Out These 4 Stocks Insiders Are Buying ↗
Although US stocks closed higher on Monday, there were a few notable insider trades. 
Via Benzinga
News headline image
MeiraGTx Announces the Presentation of Nine Posters at the American Society of Gene and Cell Therapy (ASGCT) 2023 Annual Meeting
Multiple Poster Presentations Highlight the Depth and Novelty of MeiraGTx’s Technology Platforms for Gene and Cell Therapy 
From MeiraGTx
Via GlobeNewswire
News headline image
MeiraGTx Reports First Quarter 2023 Financial and Operational Results
From MeiraGTx
Via GlobeNewswire
News headline image
MeiraGTx Announces $60 Million Private Placement of Ordinary Shares
From MeiraGTx
Via GlobeNewswire
News headline image
MeiraGTx Announces Upcoming Presentations at the Association for Research in Vision and Ophthalmology (ARVO) 2023 Annual Meeting
From MeiraGTx
Via GlobeNewswire
News headline image
MeiraGTx to Participate in Upcoming Investor Conferences
From MeiraGTx
Via GlobeNewswire
News headline image
MeiraGTx Reports Fourth Quarter and Full Year 2022 Financial and Operational Results
From MeiraGTx
Via GlobeNewswire
News headline image
MeiraGTx Announces Positive Clinical Data from the AQUAx Phase 1 Clinical Study of AAV2-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia
From MeiraGTx
Via GlobeNewswire
News headline image
MeiraGTx to Present Clinical Data from Phase 1 Trial of AAV-hAQP1 for Radiation-Induced Xerostomia on Tuesday, December 13, 2022
From MeiraGTx
Via GlobeNewswire
News headline image
MeiraGTx to Participate in Upcoming Investor Conferences
From MeiraGTx
Via GlobeNewswire
News headline image
Stocks That Hit 52-Week Lows On Thursday ↗
  During Thursday's session, 97 companies made new 52-week lows. 
Via Benzinga
News headline image
MeiraGTx Reports Third Quarter 2022 Financial and Operational Results and Receives $25 Million Investment from Johnson & Johnson Innovation - JJDC, Inc.
From MeiraGTx
Via GlobeNewswire
News headline image
MeiraGTx Announces the Upcoming Presentation of 15 Abstracts at the European Society of Gene and Cell Therapy (ESGCT) 2022 Annual Congress
Multiple Poster Presentations Highlight Versatility and Novelty of MeiraGTx’s Technology Platforms for Gene and Cell Therapy 
From MeiraGTx
Via GlobeNewswire
News headline image
Late-Breaking Phase 1/2 Data Demonstrates Safety Profile of Investigational Gene Therapy Botaretigene Sparoparvovec (AAV-RPGR) and Sustained Vision Improvement in Patients with X-Linked Retinitis Pigmentosa (XLRP)
Results from the Phase 1/2 MGT009 study presented at the American Academy of Ophthalmology (AAO) 2022 Annual Meeting set the stage for Phase 3 LUMEOS trial of botaretigene sparoparvovec in XLRP, which... 
From MeiraGTx
Via GlobeNewswire
News headline image
Kiora Pharma is Starting Human Trials of a Novel Treatment That Could Restore Vision In Patients With Inherited Blindness ↗
Kiora Pharmaceuticals Inc. (NASDAQ: KPRX), a pharmaceutical company specializing in treating eye diseases, is moving its drug candidate KIO-301 into a Phase 1b study in the third quarter of this year. 
Via Benzinga
News headline image
This Biotechnology Stock Jumped Over 360%; Here Are 106 Biggest Movers From Yesterday ↗
Gainers Quoin Pharmaceuticals, Ltd. (NASDAQ: QNRX) shares surged 360.5% to settle at $19.80 on Wednesday on above-average volume. 
Via Benzinga
News headline image
Why Poseida Therapeutics Is Trading Higher By Around 100%, Here Are 75 Stocks Moving In Wednesday's Mid-Day Session ↗
Gainers Helius Medical Technologies, Inc. (NASDAQ: HSDT) shares jumped 167% to $1.72 after dropping 13% on Tuesday. 
Via Benzinga
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.